checkAd

    DGAP-News  135  0 Kommentare BRAIN Biotech AG successfully placed new share capital for the financing of further growth initiatives - Seite 2


    The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.
    As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.
    Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

    Contact Investor Relations
    Michael Schneiders
    Head of Investor Relations & Sustainability
    Phone: +49 6251 9331-86
    Email: mis@brain-biotech.com


    Media Contact
    Dr. Stephanie Konle
    PR & Corporate Communications
    Phone: +49 6251 9331-70
    Email: stk@brain-biotech.com

    Disclaimer

    This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.
    Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

    Seite 2 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News BRAIN Biotech AG successfully placed new share capital for the financing of further growth initiatives - Seite 2 DGAP-News: BRAIN Biotech AG / Key word(s): Capital Increase BRAIN Biotech AG successfully placed new share capital for the financing of further growth initiatives 15.09.2021 / 21:51 The issuer is solely responsible for the content of this …